The improvement effect of liver dysfanction and inhibitory effect of fibrosis marker by sitagliptin or repaglinide treatment for fatty liver(liver dysfunction) patients with type2 diabetes mellitus.

Trial Profile

The improvement effect of liver dysfanction and inhibitory effect of fibrosis marker by sitagliptin or repaglinide treatment for fatty liver(liver dysfunction) patients with type2 diabetes mellitus.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Sitagliptin (Primary) ; Repaglinide
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2016 Planned End Date changed from 31 Dec 2014 to 31 Dec 2016.
    • 10 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top